MDM2 and glioblastoma: Recently, Nutlin-3, the first potent small-molecule inhibitor of MDM2 [23], was reported to be effective at inhibiting GBM cell growth in vitro[25], suggesting the validity of this experimental approach for the treatment of GBM.